AOD-9604: Evidence and Research Limitations
A modified growth-hormone fragment studied in animal models and human trials. This guide separates experimental observations, tolerability reports and claims that have not been substantiated.
What is AOD-9604?
AOD-9604 is a modified fragment derived from the C-terminal region of human growth hormone. The cited 2001 studies examine lipid metabolism and related measurements in mice. Findings in those models are not demonstrations of weight-loss benefit in people.
Human trial Evidence
Stier, Vos and Kenley’s 2013 paper reports safety and tolerability observations from a human trial programme. Read its findings within the populations, routes, durations and measurements studied. A tolerability report cannot establish general safety, safety by another route or the safety of a material from a different supplier.
The paper reports observations on IGF-1 and glucose-related measurements. These are bounded study results, not proof that the compound can never affect those systems. Safety and efficacy are separate questions.
What we have Corrected
The earlier citation to a 2013, 26-week rat study could not be established. We have removed it rather than retaining an unsupported bibliographic record. The identified human report now cited is a different publication.
We also removed the claim that AOD-9604 has Australian complementary-medicine approval for joint health: an authoritative approval record was not established in this review. We do not infer approval from research findings, a commercial description or an ingredient claim.
Earlier statements describing an exceptional safety profile and guaranteed absence of growth-factor or metabolic effects were too broad. They have been replaced with the scope and limits of the actual reports.
Compiled by the Southern Pacific Labs research team. Last updated September 2026.
Published References
- Heffernan M, Summers RJ, Thorburn A, et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.” Endocrinology, 2001. PubMed
- Heffernan MA, Thorburn AW, Fam B, et al. “Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.” International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2001. PubMed
- Moré MI, Kenley D. “Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health.” Journal of Endocrinology and Metabolism, 2014. Source
- Stier H, Vos E, Kenley D. “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans.” Journal of Endocrinology and Metabolism, 2013. SourceA human safety and tolerability report. This replaces the unverified rat-study citation with a different, identified publication; it is not evidence that the purported rat paper exists.
Browse all AOD-9604 research on PubMed →
Related Research Guides
More in Metabolic Research
A Growth Hormone cluster sibling that works upstream of GH release — tells the pituitary to produce more GH through the GHRH pathway. Different mechanism than AOD-9604, which is a fragment of GH itself working downstream on fat metabolism.
Read guide →Selective GH SecretagogueThe GH cluster sibling working through the ghrelin pathway — another upstream approach that triggers endogenous GH release. AOD-9604 takes the opposite approach, isolating one specific downstream GH function rather than amplifying the whole hormone.
Read guide →GHRH Analogue (FDA Approved)The FDA-approved GHRH analogue with full Phase 3 trial evidence — the most clinically validated upstream GH compound in the cluster. AOD-9604 is the cluster's downstream alternative, working on a different point in the same hormone's biology.
Read guide →